Microincision Vitrectomy Surgery and Intravitreal Bevacizumab as a Surgical Adjunct to Treat Diabetic Traction Retinal Detachment

Ophthalmology

Volumn 116, Issue 5, 2009, Pages 927-938

  Oshima, Yusuke ^a   Shima, Chiharu ^a   Wakabayashi, Taku ^a   Kusaka, Shunji ^a   Shiraga, Fumio ^b   Ohji, Masahito ^c   Tano, Yasuo ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GATIFLOXACIN; LEVOFLOXACIN; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CASE REPORT; CASE STUDY; CILIARY DISK; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; HUMAN; INCISION; INTERVENTION STUDY; LASER COAGULATION; MALE; MEDICAL RECORD REVIEW; OPERATION DURATION; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA DETACHMENT; RETROSPECTIVE STUDY; THERAPY EFFECT; VISUAL ACUITY; VITRECTOMY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEASIBILITY STUDIES; FEMALE; HUMANS; INJECTIONS; INTRAOPERATIVE COMPLICATIONS; LENS IMPLANTATION, INTRAOCULAR; MALE; MICROSURGERY; MIDDLE AGED; PHACOEMULSIFICATION; POSTOPERATIVE COMPLICATIONS; REOPERATION; RETINAL DETACHMENT; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

EID: 67349285875     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.11.005     Document Type: Article

References (51)

1. Aaberg T.M. Clinical results in vitrectomy for diabetic traction retinal detachment. Am J Ophthalmol 88 (1979) 246-253
2. Tolentino F.I., Freeman H.M., and Tolentino F.L. Closed vitrectomy in the management of diabetic traction retinal detachment. Ophthalmology 87 (1980) 1078-1089
3. Aaberg T.M. Pars plana vitrectomy for diabetic traction retinal detachment. Ophthalmology 88 (1981) 639-642
4. Rice T.A., Michels R.G., and Rice E.F. Vitrectomy for diabetic traction retinal detachment involving the macula. Am J Ophthalmol 95 (1983) 22-33
5. Williams D.F., Williams G.A., Hartz A., et al. Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique. Ophthalmology 96 (1989) 752-758
6. Schachat A.P., Oyakawa R.T., Michels R.G., and Rice T.A. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology 90 (1983) 522-530
7. Tolentino F.I., Cajita V.N., Gancayco T., and Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology 96 (1989) 1495-1500
8. Hershberger V.S., Augsburger J.J., Hutchins R.K., et al. Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings. Ophthalmology 111 (2004) 1215-1221
9. Lewis H., Abrams G.W., and Williams G.A. Anterior hyaloidal fibrovascular proliferation after diabetic vitrectomy. Am J Ophthalmol 104 (1987) 607-613
10. Helbig H., Kellner U., Bornfeld N., and Foerster M.H. Rubeosis iridis after vitrectomy for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 236 (1998) 730-733
11. Kadonosono K., Matsumoto S., Uchino E., et al. Iris neovascularization after vitrectomy combined with phacoemulsification and intraocular lens implantation for proliferative diabetic retinopathy. Ophthalmic Surg Lasers 32 (2001) 19-24
12. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DVRS) report 1. Ophthalmology 92 (1985) 492-502
13. Mason III J.O., Colagross C.T., Haleman T., et al. Visual outcome and risk factors for light perception and no light perception vision after vitrectomy for diabetic retinopathy. Am J Ophthalmol 140 (2005) 231-235
14. Fujii G.Y., de Juan Jr. E., Humayun M.S., et al. Initial experience using the transconjunctival sutureless vitrectomy system for vitreoretinal surgery. Ophthalmology 109 (2002) 1814-1820
15. Ibarra M.S., Hermel M., Prenner J.L., and Hassan T.S. Longer-term outcomes of transconjunctival sutureless 25-gauge vitrectomy. Am J Ophthalmol 139 (2005) 831-836
16. Lakhanpal R.R., Humayun M.S., de Juan Jr. E., et al. Outcomes of 140 consecutive cases of 25-gauge transconjunctival surgery for posterior segment disease. Ophthalmology 112 (2005) 817-824
17. Eckardt C. Transconjunctival sutureless 23-gauge vitrectomy. Retina 25 (2005) 208-211
18. Fine H.F., Iranmanesh R., Iturralde D., and Spaide R.F. Outcomes of 77 consecutive cases of 23-gauge transconjunctival vitrectomy surgery for posterior segment disease. Ophthalmology 114 (2007) 1197-1200
19. Oshima Y., Ohji M., and Tano Y. Surgical outcomes of 25-gauge transconjunctival vitrectomy combined with cataract surgery for vitreoretinal diseases. Ann Acad Med Singapore 35 (2006) 175-180
20. Okamoto F., Okamoto C., Sakata N., et al. Changes in corneal topography after 25-gauge transconjunctival sutureless vitrectomy versus after 20-gauge standard vitrectomy. Ophthalmology 114 (2007) 2138-2141
21. Kadonosono K., Yamakawa T., Uchino E., et al. Comparison of visual function after epiretinal membrane removal by 20-gauge and 25-gauge vitrectomy. Am J Ophthalmol 142 (2006) 513-515
22. Rizzo S., Genovesi-Ebert F., Murri S., et al. 25-gauge, sutureless vitrectomy and standard 20-gauge pars plana vitrectomy in idiopathic epiretinal membrane surgery: a comparative pilot study. Graefes Arch Clin Exp Ophthalmol 244 (2006) 472-479
23. Shinoda H., Shinoda K., Satofuka S., et al. Visual recovery after vitrectomy for macular hole using 25-gauge instruments. Acta Ophthalmol 86 (2008) 151-155
24. Mason III J.O., Colagross C.T., and Vail R. Diabetic vitrectomy: risks, prognosis, future trends. Curr Opin Ophthalmol 17 (2006) 281-285
25. Shah C.P., Ho A.C., Regillo C.D., et al. Short-term outcomes of 25-gauge vitrectomy with silicone oil for repair of complicated retinal detachment. Retina 28 (2008) 723-728
26. Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487
27. Adamis A.P., Miller J.W., Bernal M.T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118 (1994) 445-450
28. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29 suppl (2002) 10-14
29. Ferrara N., Damico L., Shams N., et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 (2006) 859-870
30. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
31. Chen E., and Park C.H. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 26 (2006) 699-700
32. Avery R.L., Pearlman J., Pieramici D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 (2006) 1695-1705
33. Mason III J.O., Nixon P.A., and White M.F. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142 (2006) 685-688
34. Rizzo S., Genovesi-Ebert F., Di Bartolo E., et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol 246 (2008) 837-842
35. Jonas J.B., Spandau U.H., and Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res 39 (2007) 121-122
36. Aiello L.P., Brucker A.J., Chang S., et al. Evolving guidelines for intravitreous injections. Retina 24 suppl (2004) S3-S19
37. Oshima Y., Awh C.C., and Tano Y. Self-retaining 27-gauge transconjunctival chandelier endoillumination for panoramic viewing during vitreous surgery. Am J Ophthalmol 143 (2007) 166-167
38. Oshima Y., Chow D.R., Awh C.C., et al. Novel mercury vapor illuminator combined with a 27/29-gauge chandelier light fiber for vitreous surgery. Retina 28 (2008) 171-173
39. Spitznas M. A binocular indirect ophthalmomicroscope (BIOM) for non-contact wide-angle vitreous surgery. Graefes Arch Clin Exp Ophthalmol 225 (1987) 13-15
40. Nakata K., Ohji M., Ikuno Y., et al. Wide-angle viewing lens for vitrectomy. Am J Ophthalmol 137 (2004) 760-762
41. Holladay J.T. Proper method for calculating average visual acuity. J Refract Surg 13 (1997) 388-391
42. Kellner L., Wimpissinger B., Stolba U., et al. 25-gauge vs 20-gauge system for pars plana vitrectomy: a prospective randomised clinical trial. Br J Ophthalmol 91 (2007) 945-948
43. Schiff W.M., Barile G.R., Hwang J.C., et al. Diabetic vitrectomy: influence of lens status upon anatomic and visual outcomes. Ophthalmology 114 (2007) 544-550
44. Lahey J.M., Francis R.R., and Kearney J.J. Combining phacoemulsification with pars plana vitrectomy in patients with proliferative diabetic retinopathy: a series of 233 cases. Ophthalmology 110 (2003) 1335-1339
45. Kunimoto D.Y., Kaiser R.S., and Wills Eye Retina Service. Incidence of endophthalmitis after 20- and 25-gauge vitrectomy. Ophthalmology 114 (2007) 2133-2137
46. Scott I.U., Flynn Jr. H.W., Dev S., et al. Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina 28 (2008) 138-142
47. Fung A.W., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
48. Shima C., Sakaguchi H., Gomi F., et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86 (2008) 372-376
49. Arevalo J.F., Maia M., Flynn Jr. H.W., et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92 (2008) 213-216
50. Honda S., Hirabayashi H., Tsukahara Y., and Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 246 (2008) 1061-1063
51. Sawada O., Kawamura H., Kakinoki M., et al. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 125 (2007) 1363-1366